eHealth Support Tool to Improve Quality of Life in Head and Neck Cancer Survivors

This study evaluates the development, implementation and effectiveness of a nurse-led eHealth support tool designed to improve quality of life and survivorship outcomes among adults treated for head and neck cancer. The intervention integrates symptom monitoring, self-management education, and structured survivorship support into routine follow-up care. Outcomes will include patient-reported quality of life, symptom burden, and healthcare utilization.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Head and Neck Cancer (H&N) Head and Neck Neoplasms Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beaumont RCSI Cancer Centre

Beaumont, D09V2N0, Ireland

About this study

Head and neck cancer (HNC) survivors experience significant long-term physical, functional, and psychosocial sequelae including dysphagia, speech impairment, fatigue, pain, and psychological distress. Traditional follow-up models rely on periodic clinic visits and may not adequately support self-management.

This study involves three phases:

Development of a co-designed eHealth support platform.

Implementation of the intervention within survivorship care pathways.

Evaluation of clinical effectiveness using patient-reported outcomes and healthcare utilization metrics.

The intervention integrates:

Symptom tracking Educational resources Self-management tools Structured nurse-guided follow-up

The primary hypothesis is that structured digital survivorship support will improve global quality of life compared to usual follow-up care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults ≥18 years Diagnosed with head and neck cancer Completed primary treatment (surgery, radiotherapy, chemotherapy or combination) Within 12 months post-treatment Access to smartphone/tablet/internet Able to provide informed consent

Exclusion criteria

Recurrent or metastatic disease requiring active treatment Significant cognitive impairment Inability to use digital device Non-English speakers (if tool not multilingual)

Treatment and study plan

eHealth Survivorship Support Tool

Other

A digital platform including:

Symptom monitoring Educational modules Self-management guidance Nurse-supported remote follow-up

Control

Other

Standard follow up

Primary outcomes

Quality of Life EORTC QLQ-C30 (Global Health Status scale)

Time frame: Baseline, 3 months, 6 months

Measurement Tool: EORTC QLQ-C30 (Global Health Status scale) Time Frame: Baseline, 3 months, 6 months

Sponsors and collaborators

Lead sponsor

Royal College of Surgeons, Ireland

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Feb 23, 2026
Registry last updated: Feb 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting